AFFIBODY
LIVE

Serial Number

79374502

Owner

Affibody AB

Attorney

Jessica S. Sachs

Filing Date

Mar 31, 2023

Add to watchlist:

No watchlists yet
View on USPTO

AFFIBODY Trademark

Serial Number: 79374502 • Registration: 7805540

AFFIBODY is a trademark filed by Affibody AB on March 31, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Affibody AB (3 trademarks)

Scheeles väg 2

Entity Type: 64

Trademark Details

Filing Date

March 31, 2023

Registration Date

May 27, 2025

Published for Opposition

April 8, 2025

Goods & Services

Medical and veterinary substances, preparations and articles, namely, Medical diagnostic reagents and assays for testing of bodily fluids, Clinical diagnostic reagents for medical use, Diagnostic biomarker reagents for medical purposes, Diagnostic reagents and agents for medical diagnostic use, Diagnostic reagents for clinical laboratory use, Reagents for use in medical genetic testing, Radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer, contrast media for use with imaging medical equipment; pharmaceutical preparations and substances, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of neoplasms, cancer diseases, inflammatory eye, skin, muscle and joint diseases and disorders, diseases and disorders of the immune system, autoimmune diseases and disorders, local and systemic bacterial infections, viral infections, fungal infections, central nervous system (CNS) diseases, circulatory system, respiratory system, respiratory diseases and disorders, cardiovascular diseases, renal diseases, liver diseases, skin diseases, diseases of the digestive system, gastro-intestinal diseases, eye diseases and conditions, diseases of the musculoskeletal system or connective tissue; pharmaceutical preparations and substances, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of diseases and disorders of the peripheral nervous system, namely cranial and spinal neuropathies, autonomic neuropathies, sensorimotor neuropathies and plexopathies, diseases of the blood or blood forming organs; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of disorders of the lymphatic systems namely Lymphangitis, Lymphocytosis, and Mesenteric lymphadenitis; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of metabolic diseases namely obesity, diabetes, metabolic syndrome, inborn errors of metabolism, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of diseases of the endocrine system, namely glucose homeostasis disorders, thyroid disorders, calcium homeostasis disorders and metabolic bone disease, pituitary gland disorders, sex hormone disorders and tumours of the endocrine glands; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of diseases of the genitourinary system, namely prostate, reproductive and urological diseases and disorders; diagnostic preparations and materials for medical purposes; medical therapeutic agents for regulation of biological functions, protein inhibition or activation, weight control and appetite suppression; reagents for medical, surgical, veterinary and dental use; biochemical biomarkers for medical use; diagnostic biomarker reagents for medical purposes; sanitary preparations for medical purposes

Chemical substances and materials for industrial, scientific and laboratory use other than for medical or veterinary purposes; chemical reagents other than for medical or veterinary purposes, biochemical preparations for scientific purposes; biochemical substances for scientific purposes; chemical substances for use in the production of drugs, pharmaceuticals and antibodies; reagents for scientific, laboratory, analysis, research, medical research, testing, inspection, detecting or verification use other than for medical or veterinary purposes; reagents for use in the development of antibodies other than for medical or veterinary purposes; reagents for use in scientific apparatus for chemical or biological analysis other than for medical or veterinary purposes; antibodies and antibodies-based chemicals, except for medical or veterinary use

Scientific research, technological research, product development and design in the field of biotechnics and diagnostics; medical and pharmacological research services for medical purposes in the field of biotechnics and diagnostics; medical, pharmaceutical and biotechnological laboratory research services for medical purposes in the field of biotechnics and diagnostics; scientific investigations for medical purposes; medical and scientific research, namely, conducting clinical trials for others; providing scientific information about the results of clinical trials for pharmaceutical products; scientific advisory services relating to diagnostic preparations; biochemical analysis and research for medical purposes in the field of biotechnics and diagnostics; drug discovery services; pharmaceutical products development and evaluation

Human healthcare services; medical services; providing medical information; physical examination; medical diagnostic testing, monitoring and reporting services; optical medical imaging for medical diagnostic use; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical testing for diagnostic or treatment purposes

Medical and veterinary apparatus and instruments, namely, medical apparatus and instruments for use in surgery, chromatography media in the nature of liquid chromatography apparatus for medical use in medical research; diagnostic, examination, and monitoring equipment namely, medical apparatus and instruments for diagnostic radiopharmaceutical use; screening apparatus and instruments for medical purposes, namely, ultrasonic medical diagnostic apparatus; separation instruments for medical use, namely, tubing and valve assembly set and electromechanical fluidic instrument, and other similar or related devices, which process human whole blood for the purpose of separating human blood components for use in blood transfusions and washing human red blood cells with clinical medical reagents for use in blood transfusions chromatography columns for use in affinity separation, chromatography media for use in affinity separation; gas chromatographic instruments for medical use; diagnostic imaging apparatus for medical use; medication fluid injectors

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 8, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 22, 2025 FICS
FINAL DISPOSITION PROCESSED
Dec 22, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 27, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 27, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
May 27, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 8, 2025 NPUB
PUBLISHED FOR OPPOSITION
Apr 8, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 2, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 13, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 13, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 13, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 13, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 13, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 5, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 5, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 5, 2025 ERFR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 4, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 18, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 18, 2024 OPNR
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Sep 16, 2024 GNS1
SUBSEQUENT FINAL EMAILED
Sep 16, 2024 GNSF
SUBSEQUENT FINAL REFUSAL WRITTEN
Sep 16, 2024 CFRC
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 11, 2024 GNFN
FINAL REFUSAL E-MAILED
Sep 11, 2024 GNFR
FINAL REFUSAL WRITTEN
Sep 11, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 9, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 9, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 9, 2024 TROA
REFUSAL PROCESSED BY IB
Jan 31, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 11, 2024 RFCS
REFUSAL PROCESSED BY MPU
Jan 11, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 29, 2023 RFCR
NON-FINAL ACTION WRITTEN
Dec 28, 2023 CNRT
ASSIGNED TO EXAMINER
Dec 27, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 25, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 21, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 20, 2023 REPR